Amryt Pharma
Amryt Pharma, a biopharmaceutical company headquartered in Ireland (IE), is dedicated to developing innovative treatments for rare and complex diseases. Founded in 2015, Amryt has rapidly established itself in the industry, focusing on areas such as dermatology and metabolic disorders. The company’s flagship products, including AP101 for epidermolysis bullosa and AP103 for other dermatological conditions, are distinguished by their unique formulations and targeted delivery mechanisms. Amryt Pharma has achieved significant milestones, including successful product launches and strategic partnerships, positioning itself as a leader in the rare disease market. With a commitment to improving patient outcomes, Amryt continues to expand its global reach, making a meaningful impact in the lives of those affected by challenging health conditions.
DitchCarbon Score
How does Amryt Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amryt Pharma's score of 47 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amryt Pharma's reported carbon emissions
In 2021, Amryt Pharma reported total carbon emissions of approximately 368,480 kg CO2e. This represents a significant reduction from 2020, when emissions were about 441,380 kg CO2e. The company has not disclosed specific data for Scope 1, Scope 2, or Scope 3 emissions, nor have they set formal reduction targets or initiatives as part of their climate commitments. Amryt Pharma is a current subsidiary of Chiesi Farmaceutici S.p.A., which may influence their climate strategies and reporting. However, no specific emissions reduction targets or climate pledges have been identified in their documentation. The emissions data reflects the company's operational footprint, with a reported emissions factor of about 1,950 kg CO2e per employee for Scope 1 in 2021, down from approximately 2,710 kg CO2e per employee in 2020. Overall, while Amryt Pharma has shown a positive trend in reducing emissions year-on-year, further transparency and commitment to climate initiatives would enhance their sustainability profile.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amryt Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
